PMPRB launches consultation on revised Draft Guidelines
Pharma in Brief
JUNE 21, 2020
The revised Draft Guidelines divide existing patented medicines, e. All existing patented medicines are assigned a Maximum List Price ( MLP ) tested against ex-factory list prices. Medicines falling below these thresholds, as well as biosimilars and generics, will be classified as Category II.
40 
Let's personalize your content